A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Part of paid clinical trials in Duarte, California.

Sponsor
Immunome, Inc.
Study ID
NCT06823167
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancies
  • Solid Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IM-1021 — BIOLOGICAL
    IM-1021 is an antibody-drug conjugate

Study Details

IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

Key Dates

Start date
Feb 26, 2025
Status verified
Apr 2026
Primary completion
May 31, 2028
Completion
Feb 28, 2029

Study Design

Enrollment
117 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    IM-1021 administered intravenously on a 21-day cycle, at a starting dose of 2 mg/kg.

Primary Outcome Measure

Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs) [ Time Frame: From first dose to 37 days following last dose of study treatment ]

Central Contacts

Locations (12)

FacilityCityStateZIPSite coordinators
City Of HopeDuarteCalifornia91010
Matthew Mei, MD
[email protected]
626-218-7457
Colorado Blood Cancer InstituteDenverColorado80218
Jonathan Lockhart, MD
[email protected]
720-754-4800
Cicelia Veloz
[email protected]
720-754-4800
Yale University Medical CenterNew HavenConnecticut06510
Patricia LoRusso, DO
[email protected],
475-236-1356
Emory Winship Cancer InstituteAtlantaGeorgia30322
Michael Schneider, MD
[email protected]
404-778-2695
Emma Barton-Judson
404-778-2695
Norton HealthcareLouisvilleKentucky40202
Don Stevens, MD
[email protected]
(502) 629-1234
Tatum Thompson
[email protected]
University of MichiganAnn ArborMichigan48109
Yasmin Karimi, MD
[email protected]
734-232-4312
START MidwestGrand RapidsMichigan49546
Abigail VanKirk, Site Coordinator
616-389-1824
University of Nebraska Medical CenterOmahaNebraska68105
Matthew Lunning, DO
[email protected]
402-559-7164
Gabrail Cancer CenterCantonOhio44718
Nash Gabrail, MD
[email protected]
330-492-3345
Kim Roby
330-492-3345
Sarah Cannon Research Institute - Oncology PartnersNashvilleTennessee37203
Krish Patel, MD
[email protected]
615-339-0516
MD Anderson Cancer CenterHoustonTexas77030
Sarina Piha-Paul, MD
[email protected]
713-563-1930
NEXT OncologyIrvingTexas75039
Shiraj Sen, MD
[email protected]
281-513-1643

Find similar trials in Duarte, CA

By research site
City Of Hope· Duarte, CAColorado Blood Cancer Institute· Denver, COYale University Medical Center· New Haven, CTEmory Winship Cancer Institute· Atlanta, GANorton Healthcare· Louisville, KYUniversity of Michigan· Ann Arbor, MI

Related Studies